睿知中国疾病研究地图
候选清单0

武汉武汉大学

武汉大学中南医院

Zhongnan Hospital of Wuhan University

在本站收录的 53 种疾病中,这家医院列在其中 24 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

武汉大学中南医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma11 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma2 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma97 篇牵头论文
  4. 胃癌Stomach cancer29 篇牵头论文牵头 2 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  6. 骨肉瘤Osteosarcoma19 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma6 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma12 篇牵头论文牵头 3 项开放试验
  11. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  12. 范可尼贫血Fanconi anaemia2 篇牵头论文
  13. 烟雾病Moyamoya disease13 篇牵头论文
  14. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  15. 大动脉炎Takayasu arteritis1 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis6 篇牵头论文
  17. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis0 篇牵头论文
  18. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  19. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  20. 白塞病Behçet disease2 篇牵头论文
  21. IgA 肾病IgA nephropathy1 篇牵头论文
  22. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  23. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  24. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、肝豆状核变性、胆道闭锁、肝包虫病、脊髓性肌萎缩症、法布雷病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.5%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 1120232024: 4420242025: 112025

武汉有 6 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

  2. 正在招募
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    分期
    III期
    开始
    2022-04
    登记号
    NCT05340491

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

  3. 正在招募
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    分期
    III期
    开始
    2020-03
    登记号
    NCT03907826

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术免疫治疗
论文中的科室病理/检验科耳鼻喉/头颈外科肿瘤内科影像/核医学科
牵头的论文11
  1. Spatial Metabolomics and Transcriptomics Reveal Metabolic Reprogramming and Cellular Interactions in Nasopharyngeal Carcinoma with High PD-1 Expression and Therapeutic Response.2025Theranostics免费全文
  2. Fluoroscopy-Guided Balloon Dilation for Severe Nasopharyngeal Stenosis Resulting from Radiotherapy for Nasopharyngeal Carcinoma.2024Cardiovascular and interventional radiology
  3. Intratumoral microbiota associates with systemic immune inflammation state in nasopharyngeal carcinoma.2024International immunopharmacology
  4. Single cell analysis unveils the commonality and heterogeneity between nasopharyngeal and oropharyngeal carcinoma.2024Neoplasia (New York, N.Y.)免费全文
  5. Implications of ITCH-mediated ubiquitination of SIX1 on CDC27-cyclinB1 signaling in nasopharyngeal carcinoma.2024Scientific reports免费全文
  6. Exploration of spatial heterogeneity of tumor microenvironment in nasopharyngeal carcinoma via transcriptional digital spatial profiling.2023International journal of biological sciences免费全文
  7. Knockdown of MTHFD2 inhibits proliferation and migration of nasopharyngeal carcinoma cells through the ERK signaling pathway.2022Biochemical and biophysical research communications
  8. LINC00324 suppresses apoptosis and autophagy in nasopharyngeal carcinoma through upregulation of PAD4 and activation of the PI3K/AKT signaling pathway.2022Cell biology and toxicology
  9. Cuproptosis related genes associated with Jab1 shapes tumor microenvironment and pharmacological profile in nasopharyngeal carcinoma.2022Frontiers in immunology免费全文
  10. Oral pH value predicts the incidence of radiotherapy related caries in nasopharyngeal carcinoma patients.2021Scientific reports免费全文
  11. Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  2. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial正在招募NCT05340491研究中心III期2022-04 启动
  3. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients正在招募NCT03907826研究中心III期2020-03 启动
  4. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
  5. The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT状态不明NCT01817023研究中心III期2013-04 启动
PubMed 以外找到的论文(未计入)9
  1. Development and Validation of a Multi‐Omics Model Integrating MR Radiomics and Immune Scores for Prognostic Prediction in Locally Advanced Nasopharyngeal Carcinoma2025Flavour and Fragrance Journal论文
  2. DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning2025Image and Vision Computing论文
  3. Differential sensitivities of primary tumor and lymph nodes to induction chemotherapy and definitive radiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  4. Targeting the JAK1 /STAT3 Signaling Pathway: Entinostat as a Promising Treatment for Nasopharyngeal Carcinoma2024Research Square预印本
  5. Apatinib in recurrent or metastatic head and neck cancer patients.2022Journal of Clinical Oncology会议摘要
  6. Statistical process control tools for setup reproducibility in quality control practices during nasopharyngeal carcinoma radiotherapy2022Internatuinal Journal of Radiation Research论文
  7. Induction Cisplatin and Gemcitabine Versus Cisplatin, Fluorouracil, and Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma: a Network Meta-analysis2021Research Square预印本
  8. Prognostic value of tumour infiltrating lymphocytes in nasopharyngeal carcinoma patients: Meta-Analysis2021未列出期刊研究登记
  9. The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma2021Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.07%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

武汉有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文2
  1. RIG-I promotes cell proliferation in esophageal squamous cell carcinoma by facilitating p21 degradation.2023Medical oncology (Northwood, London, England)
  2. JUND facilitates proliferation and angiogenesis of esophageal squamous cell carcinoma cell via MAPRE2 up-regulation.2023Tissue & cell
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer已完成NCT04212598牵头方(推断)II期2020-08 启动
  2. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
PubMed 以外找到的论文(未计入)7
  1. “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study2024International Journal of Radiation Oncology*Biology*Physics论文
  2. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  3. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  4. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  5. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  6. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  7. Relationship between ENO1 and Metastasis Risk and Prognosis in Esophageal squamous cell carcinoma2022Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 97 篇,占 0.7%。

牵头论文
97
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 161620212022: 131320222023: 212120232024: 191920242025: 26262025

武汉有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科病理/检验科消化/肝病科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文97
  1. A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection.2026Journal of hepatology
  2. Metabolic-immune microenvironment crosstalk mediating ICI resistance in MASH-HCC.2026Trends in endocrinology and metabolism: TEM
  3. Virus-Like Particle-Based Personalized Neoantigen Nano-Vaccine for Tumor Immunotherapy and Recurrence Prevention.2025ACS nano
  4. β-Glucan nanotubes loaded with iron diselenide for enhanced photothermal and photodynamic therapy in hepatocellular carcinoma.2025Acta biomaterialia
  5. Proteolysis-triggered RNA Interference for Mitochondrial Iron Dyshomeostasis to Activate Antitumor Immunity in Hepatic Carcinoma.2025Advanced materials (Deerfield Beach, Fla.)
  6. PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  7. Clinicopathological significance of AKT and phosphorylated AKT expression in hepatocellular carcinoma: A Meta-Analysis.2025BMC cancer免费全文
  8. Mesoporous cerium oxide nanoenzyme for Efficacious impeding tumor and metastasis via Conferring resistance to anoikis.2025Biomaterials
  9. Structurally diverse tetrahydroxanthone analogues from Paraconiothyrium sp. AC31 with pyroptosis induction through targeted inhibition of PARP1 in hepatocellular carcinoma cells.2025Bioorganic chemistry
  10. Tidal microfluidic chip-based isolation and transcriptomic profiling of plasma extracellular vesicles for clinical monitoring of high-risk patients with hepatocellular carcinoma-associated precursors.2025Biosensors & bioelectronics
  11. RNF5 exacerbates steatotic HCC by enhancing fatty acid oxidation via the improvement of CPT1A stability.2025Cancer letters
  12. Bioinformatics Identification of Lactate-Associated Genes in Hepatocellular Carcinoma: G6PD's Role in Immune Modulation.2025Cancer medicine免费全文
  13. The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma.2025Cancer research
  14. UBE2Q2 promotes tumor progression and glycolysis of hepatocellular carcinoma through NF-κB/HIF1α signal pathway.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  15. HBV upregulates TNNT1 expression through PI3K/AKT/mTOR-c-Myc axis, which in turn induces EMT and liver fibrosis in mice.2025Cellular signalling
  16. Impact of single-cell cell cycle regulation of intercellular communication on the prognosis of hepatocellular carcinoma in the tumor microenvironment.2025Clinical and experimental medicine免费全文
  17. Clinical performance evaluation of a plasma dual-target methylation test for the detection of primary liver cancer: a multicenter study.2025Clinical epigenetics免费全文
  18. Noninvasive prediction model for predicting spontaneous tumor necrosis in hepatocellular carcinoma and prognostic study.2025European journal of gastroenterology & hepatology免费全文
  19. Blocking Tim-3 enhances CD8+ T cell activity to inhibit hepatocellular carcinoma recurrence post-radiofrequency ablation.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  20. Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity.2025JCI insight免费全文
  21. MEF2D regulates T-cell function via CD70-CD27 signaling and promotes immune evasion in hepatocellular carcinoma.2025Journal of immunology (Baltimore, Md. : 1950)
  22. 3D dynamic magnetic microfluidic chip for efficient plasma extracellular vesicle enrichment and machine learning-based multiparametric diagnosis of hepatocellular carcinoma.2025Journal of nanobiotechnology免费全文
  23. LncRNA PVT1 activated by TGF-β1/Smad3 facilitates proliferation and metastasis of hepatocellular carcinoma via upregulating Smad6 and NRG1.2025Journal of translational medicine免费全文
  24. ADH1C maintains the homeostasis of metabolic microenvironment to inhibit steatotic hepatocellular carcinoma.2025Metabolism: clinical and experimental
  25. WDR4 drives tumour-associated macrophage reprogramming and tumour progression via selective translation and membrane cholesterol efflux.2025Nature cell biology
  26. Structure-based identification of potent fibroblast growth factor receptor 4 (FGFR4) inhibitors as potential therapeutics for hepatocellular carcinoma.2025PeerJ免费全文
  27. CircRNA ZFR promotes cell progression by regulating miR-96a-5p/SLC1A1 axis in hepatocellular carcinoma.2025Scientific reports免费全文
  28. Plasma proteomic analysis reveals altered protein abundances in HIV/HBV co-infection individuals with HCC and with liver cirrhosis.2025Scientific reports免费全文
  29. The potential of 18F-FDG PET/CT metabolic parameter-based nomogram in predicting the microvascular invasion of hepatocellular carcinoma before liver transplantation.2024Abdominal radiology (New York)
  30. Photothermal Fibrous Chitosan/Polydopamine Sponge for Intraoperative Hemostasis and Prevention of Tumor Recurrence in Hepatocellular Carcinoma Resection.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  31. Increases in 4-Acetaminobutyric Acid Generated by Phosphomevalonate Kinase Suppress CD8+ T Cell Activation and Allow Tumor Immune Escape.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  32. Transcriptomic Signature of 3D Hierarchical Porous Chip Enriched Exosomes for Early Detection and Progression Monitoring of Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  33. Cavin1 activates the Wnt/β-catenin pathway to influence the proliferation and migration of hepatocellular carcinoma.2024Annals of hepatology
  34. Estrogen Induces LCAT to Maintain Cholesterol Homeostasis and Suppress Hepatocellular Carcinoma Development.2024Cancer research
  35. ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma.2024Cell reports
  36. OTUB1 accelerates hepatocellular carcinoma by stabilizing RACK1 via its non-canonical ubiquitination.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  37. Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma.2024Computers in biology and medicine
  38. Nomogram predicting survival in patients with lymph node-negative hepatocellular carcinoma based on the SEER database and external validation.2024European journal of gastroenterology & hepatology免费全文
  39. A m6A regulators-related classifier for prognosis and tumor microenvironment characterization in hepatocellular carcinoma.2024Frontiers in immunology免费全文
  40. Dynamic regulation of EXO1 promotes the progression from liver fibrosis to HCC through TGF-β1/Smad signaling feedback loop.2024Hepatology communications免费全文
  41. Cabozantinib as the first step toward postimmunotherapy treatment in hepatocellular carcinoma.2024Journal of surgical oncology
  42. Genetic evidence of the causal relationship between chronic liver diseases and musculoskeletal disorders.2024Journal of translational medicine免费全文
  43. Construction and validation of a nomogram for predicting cancer-specific survival in middle-aged patients with advanced hepatocellular carcinoma: A SEER-based study.2024Medicine免费全文
  44. RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4.2024Oncogene
  45. TRIM45 facilitates NASH-progressed HCC by promoting fatty acid synthesis via catalyzing FABP5 ubiquitylation.2024Oncogene
  46. DAB2 + macrophages support FAP + fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer.2024Theranostics免费全文
  47. B-cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma.2024World journal of gastroenterology免费全文
  48. Short- and Long-Term Outcomes of Indocyanine Green Fluorescence Navigation- Versus Conventional-Laparoscopic Hepatectomy for Hepatocellular Carcinoma: A Propensity Score-Matched, Retrospective, Cohort Study.2023Annals of surgical oncology免费全文
  49. Mechanism underlying the effect of Pulsatilla decoction in hepatocellular carcinoma treatment: a network pharmacology and in vitro analysis.2023BMC complementary medicine and therapies免费全文
  50. Bioinformatics Analysis of the Prognostic Significance of VPS16 in Hepatocellular Carcinoma and Its Role in Drug Screening.2023BioMed research international免费全文
  51. FKBP11 upregulation promotes proliferation and migration in hepatocellular carcinoma.2023Cancer biomarkers : section A of Disease markers免费全文
  52. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.2023Cancer communications (London, England)免费全文
  53. Guanylate-binding proteins signature predicts favorable prognosis, immune-hot microenvironment, and immunotherapy response in hepatocellular carcinoma.2023Cancer medicine免费全文
  54. Cell Pair Algorithm-Based Immune Infiltrating Cell Signature for Improving Outcomes and Treatment Responses in Patients with Hepatocellular Carcinoma.2023Cells免费全文
  55. Cullin-associated and neddylation-dissociated 1 regulate reprogramming of lipid metabolism through SKP1-Cullin-1-F-boxFBXO11 -mediated heterogeneous nuclear ribonucleoprotein A2/B1 ubiquitination and promote hepatocellular carcinoma.2023Clinical and translational medicine免费全文
  56. GSPT1 Functions as a Tumor Promoter in Human Liver Cancer.2023Current medical science
  57. High Level of Ubiquitin Conjugate Enzyme E2O Indicates Poor Prognosis of Patients with Hepatocellular Carcinoma.2023Current medical science
  58. Serum protein biomarkers for HCC risk prediction in HIV/HBV co-infected people: a clinical proteomic study using mass spectrometry.2023Frontiers in immunology免费全文
  59. FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway.2023International journal of biological sciences免费全文
  60. Genome stability‑related lncRNA ZFPM2‑AS1 promotes tumor progression via miR‑3065‑5p/XRCC4 in hepatocellular carcinoma.2023International journal of oncology免费全文
  61. Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  62. Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis.2023Journal of translational medicine免费全文
  63. Circ_0007429/miR-637/TRIM71/Ago2 axis participates in the regulation of proliferation, migration, invasion, apoptosis, and aerobic glycolysis of HCC.2023Molecular carcinogenesis
  64. Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma.2023Molecules (Basel, Switzerland)免费全文
  65. ncRNA-mediated fatty acid metabolism reprogramming in HCC.2023Trends in endocrinology and metabolism: TEM
  66. Alternative splicing: a bridge connecting NAFLD and HCC.2023Trends in molecular medicine
  67. Advances in biomarker discovery using circulating cell-free DNA for early detection of hepatocellular carcinoma.2023WIREs mechanisms of disease免费全文
  68. Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma.2023World journal of gastroenterology免费全文
  69. NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma.2022BMC gastroenterology免费全文
  70. Upregulation of the long non-coding RNA, LIPCAR promotes proliferation, migration, and metastasis of hepatocellular carcinoma.2022Cancer biomarkers : section A of Disease markers免费全文
  71. DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome-mediated cell-cell communication.2022Cancer science免费全文
  72. NUP153 promotes HCC cells proliferation via c-Myc-mediated downregulation of P15INK4b.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  73. Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.2022Digestive diseases and sciences
  74. Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways.2022International journal of biological sciences免费全文
  75. A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma.2022International journal of biological sciences免费全文
  76. Long noncoding RNA Linc01612 represses hepatocellular carcinoma progression by regulating miR-494/ATF3/p53 axis and promoting ubiquitination of YBX1.2022International journal of biological sciences免费全文
  77. Deoxyribonuclease 1-like 3 Inhibits Hepatocellular Carcinoma Progression by Inducing Apoptosis and Reprogramming Glucose Metabolism.2022International journal of biological sciences免费全文
  78. Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene.2022Medical oncology (Northwood, London, England)免费全文
  79. A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression.2022Molecular metabolism免费全文
  80. A six lipid metabolism related gene signature for predicting the prognosis of hepatocellular carcinoma.2022Scientific reports免费全文
  81. Indocyanine green fluorescence imaging-guided laparoscopic right posterior hepatectomy.2022Surgical endoscopy
  82. DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress.2021Aging免费全文
  83. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.2021BMC cancer免费全文
  84. Identification of a five-immune gene model as an independent prognostic factor in hepatocellular carcinoma.2021BMC cancer免费全文
  85. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.2021Cancer chemotherapy and pharmacology
  86. lncRNA SNHG6 promotes hepatocellular carcinoma progression by interacting with HNRNPL/PTBP1 to facilitate SETD7/LZTFL1 mRNA destabilization.2021Cancer letters
  87. A novel long non-coding RNA RP11-286H15.1 represses hepatocellular carcinoma progression by promoting ubiquitination of PABPC4.2021Cancer letters
  88. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.2021Cell death & disease免费全文
  89. Serum deprivation-response protein induces apoptosis in hepatocellular carcinoma through ASK1-JNK/p38 MAPK pathways.2021Cell death & disease免费全文
  90. miR-143-3p inhibits proliferation and invasion of hepatocellular carcinoma cells by regulating its target gene FGF1.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  91. MiR-375 Impairs the Invasive Capabilities of Hepatoma Cells by Targeting HIF1α Under Hypoxia.2021Digestive diseases and sciences
  92. Clinical value and potential mechanisms of LINC00221 in hepatocellular carcinoma based on integrated analysis.2021Epigenomics
  93. Construction of a ceRNA network and a genomic-clinicopathologic nomogram to predict survival for HBV-related HCC.2021Human cell
  94. ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival.2021International journal of biological sciences免费全文
  95. Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  96. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis.2021Journal of immunology research免费全文
  97. Marine Natural Products: A Potential Source of Anti-hepatocellular Carcinoma Drugs.2021Journal of medicinal chemistry
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
  1. Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma状态不明NCT05575622牵头方2023-01 启动
  2. Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma状态不明NCT05282433牵头方II期2022-04 启动
  3. Clinical Study of MAK Immune Cells in the Treatment of PHC状态不明NCT05242757牵头方不分期2021-01 启动
  4. Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer状态不明NCT04688606牵头方2020-01 启动
  5. High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors状态不明NCT04033107牵头方II期2020-07 启动
  6. Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment状态不明NCT05677724牵头方(推断)2022-07 启动
  7. Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies状态不明NCT05240690牵头方(推断)I期2022-02 启动
  8. A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocellular Carcinoma: a Nomogram and Machine Learning Approaches.已完成NCT06626724牵头方(推断)2020-01 启动
  9. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  10. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC已撤回NCT05212922研究中心II期2023-06 启动
  11. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  12. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  13. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  14. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  15. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 29 篇,占 0.3%。

牵头论文
29
2021–2025 年
牵头试验
8
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 101020222023: 3320232024: 5520242025: 332025

武汉有 5 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
    分期
    未注明
    开始
    2025-04
    登记号
    NCT06464601

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:武汉大学中南医院武汉

  2. 即将招募
    A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
    分期
    未注明
    开始
    2024-08
    登记号
    NCT06496919

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:武汉大学中南医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期影像与人工智能免疫与靶向药物
论文中的科室消化/肝病科肿瘤内科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文29
  1. PRDM15 inhibits responses of Tissue-Resident memory T cells by activating PVR/TIGIT axis to mediate gastric cancer immunosuppression.2026Journal of advanced research免费全文
  2. Myeloid-Derived LGALS9-P4HB Immune Interaction Promotes Metastasis in Gastric Cancer Through Enhanced Cell Proliferation and Lipid Metabolism.2025Journal of cellular and molecular medicine免费全文
  3. Crosstalk Between Gastric Cancer and Adjacent Mucosa Reveals EDN1-EDNRA-Mediated Regulation of Cancer Stemness and Immunomodulation Networks.2025Journal of cellular and molecular medicine免费全文
  4. TAP1 promotes immune escape by activating JNK/STAT1/PD-L1 signaling in EBV-associated gastric cancer.2025Molecular and cellular biochemistry
  5. Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway.2024Drug design, development and therapy免费全文
  6. Simvastatin induces ferroptosis and activates anti-tumor immunity to sensitize anti-PD-1 immunotherapy in microsatellite stable gastric cancer.2024International immunopharmacology
  7. Development and Validation of a Comprehensive Prognostic and Depression Risk Index for Gastric Adenocarcinoma.2024International journal of molecular sciences免费全文
  8. NF1 mutation and TUBB3 amplification in gastric histiocytic sarcoma: a case report and literature review.2024Medical molecular morphology
  9. The mechanism of RGS5 regulating gastric cancer mismatch repair protein.2024Molecular carcinogenesis
  10. Upregulation of LINC00501 by H3K27 acetylation facilitates gastric cancer metastasis through activating epithelial-mesenchymal transition and angiogenesis.2023Clinical and translational medicine免费全文
  11. BGN/FAP/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer.2023International journal of biological sciences免费全文
  12. Comprehensive analysis of cuproptosis-related genes in prognosis, tumor microenvironment infiltration, and immunotherapy response in gastric cancer.2023Journal of cancer research and clinical oncology免费全文
  13. Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer.2022BMC gastroenterology免费全文
  14. Primary ovarian carcinoid arising in associated mature cystic teratoma.2022BMC women's health免费全文
  15. LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2.2022Cell death & disease免费全文
  16. MiR-192-5p/RB1/NF-κBp65 signaling axis promotes IL-10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment.2022Clinical and translational medicine免费全文
  17. Bioinformatics Analysis and Identification of Potential Genes Associated with Pathogenesis and Prognosis of Gastric Cancer.2022Current medical science
  18. LAMC1-mediated preadipocytes differentiation promoted peritoneum pre-metastatic niche formation and gastric cancer metastasis.2022International journal of biological sciences免费全文
  19. The lncRNA BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination.2022International journal of biological sciences免费全文
  20. Knockdown of hsa_circ_0043691 restrains the progression of gastric cancer by decoying miR-1294 to target pre-leukemia transcription factor 3.2022Journal of clinical laboratory analysis免费全文
  21. The lncRNA SEMA3B-AS1/HMGB1/FBXW7 Axis Mediates the Peritoneal Metastasis of Gastric Cancer by Regulating BGN Protein Ubiquitination.2022Oxidative medicine and cellular longevity免费全文
  22. Hypoxia-induced HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer.2022Redox biology免费全文
  23. Circular RNA circ_0000423 promotes gastric cancer cell proliferation, migration and invasion via the microR-582-3p/Disheveled-Axin domain containing 1 axis.2021Bioengineered免费全文
  24. The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-Interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development.2021Bioengineered免费全文
  25. Circular RNA hsa_circ_0000751 serves as a microRNA-488 sponge to suppress gastric cancer progression via ubiquinol-cytochrome c reductase core protein 2 regulation.2021Bioengineered免费全文
  26. Adenocarcinoma with Mixed Subtypes in the Early and Advanced Gastric Cancer.2021Canadian journal of gastroenterology & hepatology免费全文
  27. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.2021Cancer medicine免费全文
  28. Magnifying endoscopy in detecting early gastric cancer: A network meta-analysis of prospective studies.2021Medicine免费全文
  29. Immortal time bias exaggerates the effect of metformin on the risk of gastric cancer: A meta-analysis.2021Pharmacological research
中文论文(未计入)1
  1. [Immune-related genes and their determined immune cell microenvironment to predict the prognosis of gastric adenocarcinoma].2022Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors状态不明NCT04033107牵头方II期2020-07 启动
  2. Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection状态不明NCT03392103牵头方II期2017-01 启动
  3. A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer即将招募NCT06464601牵头方(推断)2025-04 启动
  4. A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors即将招募NCT06496919牵头方(推断)2024-08 启动
  5. The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer状态不明NCT03154983牵头方(推断)II期2017-05 启动
  6. Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer已完成NCT02528110牵头方(推断)II期2015-08 启动
  7. Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer状态不明NCT01889303牵头方(推断)II期2013-05 启动
  8. Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis状态不明NCT00454519牵头方(推断)II期2007-03 启动
  9. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  10. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  11. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839研究中心III期2017-04 启动
  12. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

武汉有 18 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.8%。

牵头论文
19
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 5520232024: 2220242025: 442025

武汉有 31 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文19
  1. Trimerization-Enhanced NIR-II/Photoacoustic Nanoprobes for Precision Osteosarcoma Imaging.2025Analytical chemistry
  2. Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.2025BMC cancer
  3. Near-infrared light-enhanced polydopamine-based multifunctional nanoparticles for combination of chemodynamic and NO gas therapy in the treatment of osteosarcoma.2025International journal of biological macromolecules
  4. HEY1 promotes the development and metastasis of osteosarcoma through CD44/EGFR/FAK pathway.2025Journal of cellular and molecular medicine
  5. Bone Destruction-Chemotactic Osteoprogenitor Cells Deliver Liposome Nanomedicines for the Treatment of Osteosarcoma and Osteoporosis.2024ACS nano
  6. Metastatic dedifferentiated liposarcoma of the mediastinum with osteosarcomatous differentiation: A case report.2024Medicine
  7. Autophagy and its role in osteosarcoma.2023Cancer medicine
  8. NSUN2 promotes osteosarcoma progression by enhancing the stability of FABP5 mRNA via m5C methylation.2023Cell death & disease
  9. Overexpression of HSPB6 inhibits osteosarcoma progress through the ERK signaling pathway.2023Clinical and experimental medicine
  10. Aa-Z2 triggers ROS-induced apoptosis of osteosarcoma by targeting PDK-1.2023Journal of translational medicine
  11. 3-AP inhibits the growth of human osteosarcoma by decreasing the activity of the iron-dependent pathway.2023Medical oncology (Northwood, London, England)
  12. Nigericin exerts anticancer effects through inhibition of the SRC/STAT3/BCL-2 in osteosarcoma.2022Biochemical pharmacology
  13. Peptide-based semiconducting polymer nanoparticles for osteosarcoma-targeted NIR-II fluorescence/NIR-I photoacoustic dual-model imaging and photothermal/photodynamic therapies.2022Journal of nanobiotechnology
  14. Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.2022Medical oncology (Northwood, London, England)
  15. Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis.2021Biochemical and biophysical research communications
  16. Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a PIM1 kinase inhibitor.2021Journal of controlled release : official journal of the Controlled Release Society
  17. EWS-FLI1-targeting peptide identifies Ewing sarcoma tumor boundaries and lymph node metastasis via near-infrared imaging.2021Molecular oncology
  18. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.2021Oxidative medicine and cellular longevity
  19. In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy.2021Theranostics
早期论文(2016–2020 年)12
  1. Polyethylenimine-dextran-coated magnetic nanoparticles loaded with miR-302b suppress osteosarcoma in vitro and in vivo.2020Nanomedicine (London, England)
  2. Overexpression of miR-335 inhibits the migration and invasion of osteosarcoma by targeting SNIP1.2019International journal of biological macromolecules
  3. Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells.2018Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.2018Drug metabolism and disposition: the biological fate of chemicals
  5. L‑mimosine induces caspase‑9‑mediated apoptosis in human osteosarcoma cells.2018Molecular medicine reports
  6. Survival outcome among patients with Ewing's sarcoma of bones and joints: a population-based cohort study.2018Sao Paulo medical journal = Revista paulista de medicina
  7. HIF-1α inhibits IDH-1 expression in osteosarcoma.2017Oncology reports
  8. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.2017Oncotarget
  9. MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2.2017Scientific reports
  10. miR-140-5p attenuates chemotherapeutic drug-induced cell death by regulating autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells.2016Bioscience reports
  11. Downregulation of IDH2 exacerbates the malignant progression of osteosarcoma cells via increased NF-κB and MMP-9 activation.2016Oncology reports
  12. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.2016Scientific reports

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 9 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.5%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 3320232024: 0020242025: 002025

武汉有 11 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 6 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.7%。

牵头论文
12
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 2220232024: 4420242025: 112025

武汉有 3 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
    分期
    不分期
    开始
    2025-06
    登记号
    NCT07305337

    年龄 18 岁 至 90 岁(登记的条件)

    牵头:武汉大学中南医院武汉

  2. 正在招募
    Helical Tomotherapy in Multiple Myeloma
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05970198

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:武汉大学中南医院武汉

  3. 邀请入组
    AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
    分期
    未注明
    开始
    2018-08
    登记号
    NCT07410403

    年龄未注明(登记的条件)

    牵头:武汉大学中南医院武汉

  4. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  5. 即将招募
    A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
    分期
    I/II期
    开始
    2025-02
    登记号
    NCT06799676

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层联合用药肾脏与骨骼并发症
牵头的论文12
  1. Compound Kushen Injection suppresses multiple myeloma progression via TOP1-targeted coordination of DNA damage and endoplasmic reticulum stress.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.2024Annals of hematology
  3. Clinical and immunological characteristics of high-risk double-hit multiple myeloma.2024BMC cancer免费全文
  4. The casual relationship between autoimmune diseases and multiple myeloma: a Mendelian randomization study.2024Clinical and experimental medicine免费全文
  5. Chemotherapy plus therapeutic plasmapheresis with 4% human albumin solution in multiple myeloma patients with acute kidney injury: a prospective, open-label, proof-of-concept study.2024Renal failure免费全文
  6. Global burden of hematologic malignancies and evolution patterns over the past 30 years.2023Blood cancer journal免费全文
  7. Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.2023Journal of cancer research and clinical oncology免费全文
  8. Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia.2022Contrast media & molecular imaging免费全文
  9. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.2022Hematological oncology
  10. Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma.2022Journal of immunology research免费全文
  11. Management of acute spinal cord compression in multiple myeloma.2021Critical reviews in oncology/hematology
  12. Identification of novel combined biomarkers in the diagnosis of multiple myeloma.2021Hematology (Amsterdam, Netherlands)
中文论文(未计入)1
  1. [Changes of Serum Complement C1q in Patients with Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. Randomised Controlled Trial of Artificial Intelligence-assisted Health Education正在招募NCT07305337牵头方不分期2025-06 启动
  2. Plasma-free Replacement in Patients With Multiple Myeloma已完成NCT05251896牵头方不分期2020-01 启动
  3. Helical Tomotherapy in Multiple Myeloma正在招募NCT05970198牵头方(推断)不分期2023-06 启动
  4. AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities邀请入组NCT07410403牵头方(推断)2018-08 启动
  5. Double Filtration Plasmapheresis Combined With Chemotherapy状态不明NCT04836871牵头方(推断)I期2021-05 启动
  6. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  7. A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma即将招募NCT06799676研究中心I/II期2025-02 启动
  8. ATG-010(Selinexor) in Combination With Chemotherapy in RRMM状态不明NCT04877275研究中心II期2021-05 启动
  9. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma状态不明NCT04674514研究中心I/II期2021-04 启动
  10. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

武汉有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

武汉有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 13 篇,占 3.6%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 4420232024: 5520242025: 112025

武汉有 3 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题血管重建手术影像与脑血流儿童
论文中的科室神经外科
牵头的论文13
  1. Treatment strategies and prognostic analysis of moyamoya disease associated with single intracranial aneurysm.2025Clinical neurology and neurosurgery
  2. Association of retrograde bypass flow depth along cortical recipient arteries with revascularization outcomes in direct bypass surgery for Moyamoya disease.2024Clinical neurology and neurosurgery
  3. Intraoperative evaluation of local cerebral hemodynamic change by laser speckle contrast imaging for predicting postoperative cerebral hyperperfusion during STA-MCA bypass in adult patients with moyamoya disease.2024Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism免费全文
  4. Role of scalp arteries in revascularization after side to side anastomosis in moyamoya disease patients.2024Scientific reports免费全文
  5. Arterialized Vein Immediately After Direct Bypass Surgery Indicates Cerebral Hyperperfusion Syndrome in Moyamoya Disease.2024Stroke
  6. Treatment of moyamoya disease with intracranial aneurysm by surgical clipping combined with encephalo-duro-myo-synangiosis surgery: a case report and literature review.2024The International journal of neuroscience
  7. Increase in age at onset of moyamoya disease in China over 25 years.2023Brain and behavior免费全文
  8. Assessment of plasma soluble Tie-2 level to distinguish moyamoya disease from atherosclerotic cerebrovascular disease and predict postoperative neovascularization.2023Journal of neurosurgery
  9. A flow self-regulating superficial temporal artery-middle cerebral artery bypass based on side-to-side anastomosis for adult patients with moyamoya disease.2023Journal of neurosurgery
  10. The Progression of Pathophysiology of Moyamoya Disease.2023Neurosurgery
  11. The contralateral progression in a cohort of Chinese adult patients with unilateral moyamoya disease after revascularization: a single-center long-term retrospective study.2022Acta neurochirurgica免费全文
  12. How to choose the surgical side when cerebral blood flow and cerebrovascular response are contradictory in bilateral moyamoya disease?: A case report.2022Medicine免费全文
  13. An ecological comparison study on the causal association between leptospirosis and moyamoya disease in Hubei, China, 2017-2019.2021Clinical neurology and neurosurgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome正在招募NCT07894107研究中心2026-08 启动
PubMed 以外找到的论文(未计入)3
  1. Recent Advances for Global Perspectives on Etiology, Pathophysiology, Clinical Presentations, and Management of Moyamoya Disease2024World Journal of Neuroscience论文
  2. An Ecological Comparison Study On The Causal Association Between Leptospirosis and Moyamoya Disease in Hubei, China, 2017-20192021Research Square预印本
  3. The Association Between RNF213 , MMP3 , and Moyamoya Disease: Screening the Full Exons of Susceptibility Genes in Families with Moyamoya Disease2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

武汉有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 4 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. Ischemic stroke as the first manifestation of Takayasu arteritis: high resolution magnetic resonance imaging.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.6%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 3320232024: 0020242025: 332025

武汉有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年没有牵头肺淋巴管平滑肌瘤病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Sporadic lymphangioleiomyomatosis with multiple atypical features: A case report and literature review.2018Indian journal of pathology & microbiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

武汉有 6 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 3 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

武汉有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室病理/检验科消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 8 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文1
  1. Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.2021International urology and nephrology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  2. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 5 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

武汉有 3 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

武汉有 4 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

武汉大学中南医院

Zhongnan Hospital of Wuhan University

武汉

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Zhongnan Hospital; Wuhan University Zhongnan Hospital; Zhongnan hospital of Wuhan University

提出更正下载数据